 | | Vol. 4.35 – 18 September, 2020 |
| |
|
|
| The polygenic risk score predicted the susceptibility to drug-induced liver injury in patients treated with fasiglifam, amoxicillin–clavulanate or flucloxacillin and in primary hepatocytes and stem cell-derived organoids from multiple donors treated with over ten different drugs.
[Nature Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists observed that Steatohepatitis-associated circRNA ATP5B Regulator (SCAR), which is located in mitochondria, inhibited mitochondrial ROS output and fibroblast activation.
[Cell] |
|
|
|
| Isothermal titration calorimetry and multiphoton microscopy showed that L9 and the other most protective mAbs bound PfCSP with two binding events and mediated protection by killing SPZ in the liver and by preventing their egress from sinusoids and traversal of hepatocytes.
[Immunity] |
|
|
|
| Investigators generated liver-specific sphingosine kinase 2 (SphK2) knockout mice, demonstrating that SphK2 in the liver was essential for insulin sensitivity and glucose homeostasis.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers established murine and human 3D co-culture models of liver tumor organoids with cancer associated fibroblasts (CAFs). CAFs promoted tumor organoid growth in co-culture with direct cell-cell contact and in trans-well system via paracrine signaling.
[Cellular and Molecular Gastroenterology and Hepatology] |
|
|
|
| Functional experiments revealed that knockdown of hsa_circ_0001955 markedly inhibited proliferation, migration and invasion of hepatocellular carcinoma, and its overexpression led to opposite effects.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| The authors showed that LIN28B-AS1 was expressed in established/primary human hepatocellular carcinoma (HCC) cells and HCC tissues. RNA-immunoprecipitation and RNA pull-down results confirmed that LIN28B-AS1 directly associated with IGF2BP1 protein in HCC cells.
[Cell Death & Disease] |
|
|
|
| Investigators established a model of hepatocellular carcinoma (HCC) with intrahepatic metastasis and noticed some differential appearances in different HCC cell lines. Luciferase-transfected HCC cell lines MHCC97-H and PLC/PRF/5 were inoculated into SCID mice via spleen.
[Scientific Reports] |
|
|
|
| In Huh-7 cells harbouring the hepatitis C virus (HCV) replicon, Rubicon knockdown downregulated the expression of type 1 interferon-related genes and upregulated HCV replication.
[Scientific Reports] |
|
|
|
| Cyanidin-3-O-glucoside increased glucose uptake in HepG2 cells and C2C12 myotubes and induced the rate of hepatic fatty acid oxidation. C3G directly interacted with and activated PPARs, with the highest affinity for PPARα.
[Communications Biology] |
|
|
|
|
| Scientists summarize recent discoveries, which are specific ceRNA regulatory networks (lncRNA/circRNA-miRNA-mRNA) in hepatocellulr carcinoma and discuss their clinical significance.
[Cancers] |
|
|
|
| Investigators summarize hepatocellulr carcinoma (HCC), its staging system, current therapy and immunotherapy medications currently being utilized or studied in the treatment of HCC with the hopes of highlighting what is being done and suggesting what needs to be done in the future to champion this therapy as an effective option.
[International Journal of Molecular Sciences] |
|
|
|
| The authors discuss current knowledge of the roles and functions of AU-rich element-binding proteins (AUBPs) in liver diseases and cancer. The relevance of AUBPs as potential biomarkers for different stages of FLD and HCC, or as therapeutic targets for these diseases, are also highlighted.
[International Journal of Molecular Sciences] |
|
|
|
|
| Roche have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® in combination with Avastin® for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy.
[Roche] |
|
|
|
| 89bio, Inc. has announced positive topline results from its Phase Ib/IIa trial with BIO89-100, an investigational FGF21 analog, in patients with nonalcoholic steatohepatitis (NASH).
[89bio, Inc.] |
|
|
|
|
|
|
|
| | Medical University of South Carolina – Charleston, South Carolina, United States |
|
|
|
| | Chr. Hansen A/S – Hørsholm, Denmark |
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
| | Purdue University – West Lafayette, Indiana, United States |
|
|
|
| | Old Dominion University – Norfolk, Virginia, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
